Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation

  title={Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation},
  author={M. Losen and P. Martinez-Martinez and M. Phernambucq and J. Schuurman and P. Parren and M. D. de Baets},
  journal={Annals of the New York Academy of Sciences},
  • M. Losen, P. Martinez-Martinez, +3 authors M. D. de Baets
  • Published 2008
  • Chemistry, Medicine
  • Annals of the New York Academy of Sciences
  • Myasthenia gravis (MG) is an autoimmune disease caused by antibodies mainly directed to the acetylcholine receptor (AChR) of the neuromuscular junction. Induction of antigenic modulation and complement activation by such autoantibodies leads to ultrastructural damage of the postsynaptic membrane and loss of AChR and associated proteins. Reduction of antigenic modulation by increasing the expression of the receptor‐associated anchor protein, rapsyn, or by functionally monovalent competing IgG4… CONTINUE READING
    25 Citations
    Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction
    • 97
    Autoimmune myasthenia gravis
    • 31
    The auto-antigen repertoire in myasthenia gravis
    • 57
    Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil
    • 20
    • PDF
    Current and emerging therapies for the treatment of myasthenia gravis
    • 57
    • PDF


    Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
    • 420